Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
PubblicatoCarla Romani Modificato 6 anni fa
1
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, Giacomo Allegrini, Fotios Loupakis, Enrico Vasile, Samanta Cupini, Irene Stasi, Lisa Salvatore, Chiara Cremolini, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Francesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, Mauro Magnani, Alfredo Falcone Critical Reviews in Oncology / Hematology Volume 78, Issue 3, Pages (June 2011) DOI: /j.critrevonc Copyright © 2010 Elsevier Ireland Ltd Terms and Conditions
2
Fig. 1 PFS and OS curves. (A) PFS in all patients. (B) OS in all patients. (C) PFS according to KRAS mutational status. (D) OS according to KRAS mutational status. (E) PFS according to BRAF mutational status. (F) OS according to BRAF mutational status. (G) PFS according to KRAS and BRAF mutational status. (H) OS according to KRAS and BRAF mutational status. n, number; pts, patients; wt, wild-type; mut, mutated. Critical Reviews in Oncology / Hematology , DOI: ( /j.critrevonc ) Copyright © 2010 Elsevier Ireland Ltd Terms and Conditions
Presentazioni simili
© 2024 SlidePlayer.it Inc.
All rights reserved.